Mey, Gabrielle M.
Evonuk, Kirsten S.
Chappell, McKenzie K.
Wolfe, Laura M.
Singh, Rupesh
Batoki, Julia C.
Yu, Minzhong
Peachey, Neal S.
Anand-Apte, Bela
Bermel, Robert
Ontaneda, Daniel
Nakamura, Kunio
Mahajan, Kedar R.
DeSilva, Tara M. http://orcid.org/0000-0002-1212-5762
Funding for this research was provided by:
National Science Foundation (1648822)
National Eye Institute (P30EY025585, T32 EY024236, R01EY025687, R01EY032342)
National Institute of Neurological Disorders and Stroke (K23NS109328)
Research to Prevent Blindness
National Multiple Sclerosis Society (FG-1807-31882, FG-2108-38411)
Article History
Received: 15 April 2022
Accepted: 28 May 2022
First Online: 15 June 2022
Change Date: 15 July 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s40478-022-01405-9
Declarations
:
: Dr. Robert Bermel discloses consultation for Astra Zeneca, Biogen, EMD Serono, Genzyme/Sanofi, Genentech/Roche, LabCorp, Novartis, TG Therapeutics, and VielaBio. Dr. Robert Bermel also discloses research support from Biogen, Genentech, and Novartis, and shares rights to intellectual property underlying the Multiple Sclerosis Performance Test, currently licensed to Qr8 Health and Biogen. Dr. Daniel Ontaneda discloses research support from Genentech, Genzyme, and Novartis and consulting fees from Biogen Idec, Genentech/Roche, Genzyme, Janssen, Novartis, and Merck. Dr. Kunio Nakamura discloses personal compensation for licensing from Biogen and research support from Genzyme and Biogen. All other authors declare no competing interests.